{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-197943","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.052603+00:00","generated_at":"2026-05-31T10:21:37.157928+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zevra Therapeutics prices $60M common stock offering at $6.50/share; net proceeds ~$56.1M","bullets":["9,230,770 shares sold at $6.50; underwriters have 30-day option for 1,384,615 additional shares.","Net proceeds estimated at $56.1M after underwriting discounts and offering expenses.","Proceeds to fund pre-commercial launch of arimoclomol, OLPRUVA support, and development of celiprolol and KP1077.","Company believes net proceeds plus existing cash will fund operations through Q1 2026; closing expected Aug 12, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-197943","json":"https://secwatch.observer/filing/0001193125-24-197943.json","markdown":"https://secwatch.observer/filing/0001193125-24-197943.md","text":"https://secwatch.observer/filing/0001193125-24-197943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000119312524197943/0001193125-24-197943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000119312524197943/d723355d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:21:37.157928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}